e-learning
resources
Paris 2018
Wednesday, 19.09.2018
Lung cancer: novel molecular markers and mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhibitory effects of mitochondrial TRAP1 on gefitinib-resistancein non-small lung cancer cells
K. Hwang (Iksan, Republic of Korea), S. Oh (Iksan, Republic of Korea), E. Jeong (Iksan, Republic of Korea), H. Kim (Iksan, Republic of Korea)
Source:
International Congress 2018 – Lung cancer: novel molecular markers and mechanisms
Session:
Lung cancer: novel molecular markers and mechanisms
Session type:
Oral Presentation
Number:
5379
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Hwang (Iksan, Republic of Korea), S. Oh (Iksan, Republic of Korea), E. Jeong (Iksan, Republic of Korea), H. Kim (Iksan, Republic of Korea). Inhibitory effects of mitochondrial TRAP1 on gefitinib-resistancein non-small lung cancer cells. 5379
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Deguelin enhances chemosensitivity of non-small cell lung cancer cells
Source: Eur Respir J 2006; 28: Suppl. 50, 336s
Year: 2006
Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line
Source: Annual Congress 2007 - Biology in thoracic oncology
Year: 2007
Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012
Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
Source: International Congress 2017 – Gene signatures in bronchial diseases
Year: 2017
Targeted therapy in non-small cell lung cancer
Source: Breathe 2012; 8: 206-215
Year: 2012
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007
Proliferative activity of non-small cell lung cancer after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 328s
Year: 2005
Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
Update on nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 173-185
Year: 2010
Expression of p53, Bcl-2 and Bax in non-small cell lung cancer
Source: Eur Respir J 2007; 30: Suppl. 51, 512s
Year: 2007
Choice of endogenous control for gene expression in nonsmall cell lung cancer
Source: Eur Respir J 2005; 26: 1002-1008
Year: 2005
IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer
Source: Eur Respir J , 49 (4) 1600711; DOI: 10.1183/13993003.00711-2016
Year: 2017
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept